Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population

Lena Tschiderer, Lisa Seekircher, Lukas Richter, Dorothee von Laer, Cornelia Lass-Flörl, Lukas Forer, Sebastian Schönherr, Florian Krammer, Sabine Embacher-Aichhorn, Herbert Tilg, Günter Weiss, Franz Allerberger, Peter Willeit

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


This study aimed to determine the impact of ultra-rapid rollout vaccination on incidence of SARS-CoV-2 infection. Vaccination with BNT162b2 was provided to 66.9% of eligible residents of the Schwaz district in Tyrol, Austria, within six days per dose (first dose: 11–16 March 2021, second dose: 8–13 April 2021). Of 11,955 individuals enrolled at nine vaccination centers (median age 44.6 years; 51.3% female), 71 had incident SARS-CoV-2 over a six-month follow-up. Incidence rates per 100,000 person-weeks were 92.3 (95% confidence interval [CI]: 70.8–120.2) at weeks 1–5 and 6.4 (3.9–10.4) at ≥6 weeks after dose 1. In these two periods, effectiveness of the vaccination campaign to reduce incident SARS-CoV-2 was 58.6% (50.8%–65.2%) and 91.1% (89.6%–92.3%) in study participants and 28.3% (23.1%–33.0%) and 64.0% (61.7%–66.1%) in the Schwaz district, compared with districts with slower vaccination rollout. Therefore, the vaccination campaign in the Schwaz district illustrates the impact of accelerated vaccination rollout in controlling the pandemic.

Original languageEnglish
Article number105380
Issue number11
StatePublished - 18 Nov 2022


  • Health sciences
  • Immunology
  • Population


Dive into the research topics of 'Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population'. Together they form a unique fingerprint.

Cite this